MAPT and tauopathy: Liraglutide, a drug which stimulates insulin production, has been shown to prevent and decrease the phosphorylation of tau in a mouse model of type II diabetes (Wyss-Coray and Mucke, 2002) and to decrease phosphorylated tau and improve motor function in a mouse model of tauopathy (hTauP301L); also, there is a report about improvement in motor function on this (Ransohoff, 2016a).